Browse treatments

…an OS was 16.8 months (95% CI: 14.5, 20.0) in the ivonescimab + chemotherapy group vs 14.1 months (95% CI: 12.8, 16.3) in the placebo + chem…

…observational study confirms that patients with NSCLC receiving chemotherapy experience significant psychological distress and impaired QoL.…

…usions Our findings indicate that Dabrafenib and cetuximab with chemotherapy are effective and tolerable first-line and second-line regimens…

…nd increased IFNγ+TNF+CD8+ T cells. Additionally, we found that chemotherapy upregulated the neutrophil chemoattractant C-X-C motif chemokin…

…combined with chemotherapy becomes cost-effective compared with chemotherapy alone for treating advanced oesophageal squamous cell carcinoma…

…ferred preventative strategy for patients at risk of HFS during chemotherapy.PROSPERO registration number CRD42025643635…

…d with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). …

…309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall…

… gene-negative nsNSCLC patients, first-line PD-1 inhibitor plus chemotherapy demonstrated significantly improved PFS compared to bevacizumab…

…xiety, depression, distress) in patients with cancer undergoing chemotherapy.Methods This systematic review protocol is developed in accorda…

…s substantial variation in treatment use between jurisdictions. Chemotherapy use ranged from 23% in Northern Ireland to 45% in Norway, while…

…sed on a prospective cohort study, malnutrition may not predict chemotherapy response. However, it was associated with a reduced number of c…